Maitalon (Drospirenone, Ethinylestradiol)

Maitalon, a combined oral contraceptive, is used to manage reproductive health by influencing hormonal pathways.

• Contraception: prevents pregnancy by suppressing ovulation and altering cervical mucus.
• Menstrual cycle regulation: promotes more predictable bleeding patterns and reduces menstrual discomfort.

• Drospirenone and ethinylestradiol bind to progesterone and estrogen receptors, respectively, suppressing the hypothalamic‑pituitary‑gonadal axis. This inhibition reduces luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release, preventing ovulation. The estrogen component stabilises the endometrial lining, while the progestin component thickens cervical mucus, creating multiple barriers to fertilisation and implantation.

Maitalon may cause a range of adverse reactions. The most frequently reported events are generally mild and transient.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Breast tenderness: discomfort or swelling of the breasts.
• Headache: occasional tension‑type headache.
• Spotting: irregular bleeding between periods.

Serious or Rare Side Effects

• Blood clots: deep‑vein thrombosis, pulmonary embolism, or arterial thrombosis.
• Severe hypertension: sudden increase in blood pressure.
• Liver dysfunction: abnormal liver enzymes or jaundice.

Before prescribing Maitalon, clinicians should evaluate individual risk factors and counsel patients on safe use.

• Assess thrombotic risk: review personal and family history of clotting disorders.
• Screen for cardiovascular disease: avoid in patients with uncontrolled hypertension or coronary artery disease.
• Evaluate liver function: contraindicated in active liver disease.
• Counsel on smoking: smoking increases thrombotic risk, especially in women over 35.
• Review medication list: certain drugs can reduce contraceptive efficacy.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Maitalon can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce hormone levels.
• Rifampin and other strong antibiotics: can diminish contraceptive efficacy.
• Protease inhibitors (e.g., ritonavir): may increase hormone concentrations.
• St. John's wort: herbal inducer that lowers contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

• Antifungals such as ketoconazole: may raise hormone levels, requiring monitoring.
• Selective serotonin reuptake inhibitors (SSRIs): can increase bleeding tendency.
• Diuretics: may affect fluid balance and blood pressure, warranting observation.